Advertisement


Shridar Ganesan, MD, PhD, on Mutation Burden and Immunotherapy

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discusses mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.



Related Videos

CNS Cancers

Holger N. Lode, MD: Neuroblastoma Survival Update

Holger N. Lode, MD, of the University of Greifswald, discusses the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO and killer-c...

CNS Cancers

Holger N. Lode, MD: Neuroblastoma Survival Update (German Language Version)

Holger N. Lode, MD, of the University of Greifswald, discusses in German the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO an...

Solid Tumors

Prasad S. Adusumilli, MD, on Solid Tumors: CAR T Cells and Immune Checkpoint Blockade

Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses a way to promote functional persistence of CAR T cells as an ideal strategy for solid tumor immunotherap...

Solid Tumors

Stephen Gottschalk, MD, on CAR T Cells for Solid Tumors: What Are the Challenges?

Stephen Gottschalk, MD, of Baylor College of Medicine and Texas Children’s Hospital, discusses combining CAR T cells with checkpoint blockade or targeted treatments to improve their a...

Lung Cancer

Roy S. Herbst, MD, PhD, on Lung Cancer With Immune Checkpoints: Promising Combinations

Roy S. Herbst, MD, PhD, of the Yale Cancer Center, discusses immunotherapy as a standard of care in lung cancer, critical biomarkers, and scientifically guided combination treatment, ...

Advertisement

Advertisement



Advertisement